Premium
P2‐062: RILUZOLE AS AN EARLY THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE
Author(s) -
Hascup Kevin N.,
Broderick Sarah O.,
Britz Jesse,
Hascup Erin R.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.747
Subject(s) - riluzole , glutamate receptor , morris water navigation task , glutamatergic , hippocampal formation , neuroprotection , dentate gyrus , neuroscience , barnes maze , medicine , endocrinology , pharmacology , psychology , anesthesia , spatial learning , receptor
Background: Evidence supports soluble amyloid-b (Ab)42 as the neurotoxic species associated with Alzheimer’s disease (AD) that can stimulate presynaptic glutamate release. Furthermore, 2-4 month old AbPP/PS1, a model of Ab42 accumulation, has elevated hippocampal glutamate compared to age-matched C57BL/6J mice. Despite glutamate’s role in learning and memory, chronically elevated glutamate levels may cause excitoxicity and cognitive decline associated with AD. We hypothesized that prodromal treatment with neuroprotective Riluzole in AbPP/PS1 mice would